1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Puttlitz

Examiner Puttlitz Karl J

1646-PUTTLITZ-KARL-J

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
514 — Drug, bio-affecting and body treating compositions
562 — Organic compounds -- part of the class 532-570 series
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
435 — Chemistry: molecular biology and microbiology
560 — Organic compounds -- part of the class 532-570 series
504 — Plant protecting and regulating compositions
210 — Liquid purification or separation
436 — Chemistry: analytical and immunological testing
528 — Synthetic resins or natural rubbers -- part of the class 520 series
Phone:(571) 272-0645
Email:karl.puttlitz@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:23 years
Grade:GS-14

Grant Rate and Difficulty Ranking

69
3-Year Grant rate: 64% over 577 cases
Difficulty: Harder
Difficulty Percentile: 69th

With Examiner Puttlitz, you have a 64% chance of getting an issued patent by 3 years after the first office action. Examiner Puttlitz is a harder examiner and in the 69th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Puttlitz, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Puttlitz's grant rate is higher than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Puttlitz 1.5
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Puttlitz has granted 318 of 487 cases without any applicant-requested interviews for a grant rate of 65%.

Grant Rate with Interview

Examiner Puttlitz has granted 54 of 90 cases with at least one applicant-requested interview for a grant rate of 60%.

Interview Benefit

With Examiner Puttlitz, conducting an interview decreases your chance of getting a patent granted by 8%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18001566 Anti-Ctla4 Monoclonal Antibodies And Chimeric Antigen Receptors Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17796707 Treatment Of Cancer Patented View
17605766 Amatoxin Antibody-Drug Conjugates And Uses Thereof Patented View
17793419 Mr1 Ligands And Pharmaceutical Compositions For Immunomodulation Abandoned View
18903935 Antibody-Oligonucleotide Conjugate Compositions And Methods Of Inducing Dmd Exon 45 Skipping Abandoned View
18957324 Bispecific Antibody-Camptothecin Drug Conjugate And Pharmaceutical Use Thereof Patented View
17862254 Liquid Chromatography Assay For Determining Aav Capsid Ratio Patented View
17615815 Adjuvant Combinations As Foliar Uptake Accelerator For Herbicidal Compositions Patented View
17994657 Mitigating Necrosis In Transgenic Glyphosate-Tolerant Cotton Plants Treated With Herbicidal Glyphosate Formulations Abandoned View
18225567 Protein-Antiviral Compound Conjugates Patented View
16060009 Cell Penetrating Cyanine-Coupled Antibodies Patented View
17997240 Anti-Cd103 Antibodies Patented View
18914023 Anti-Tissue Factor Antibodies And Antibody Conjugates, Compositions Comprising Anti-Tissue Factor Antibodies Or Antibody Conjugates, And Methods Of Making And Using Anti-Tissue Factor Antibodies And Antibody Conjugates Patented View
18620025 Antibody, Linkers, Payload, Conjugates And Applications Thereof Patented View
17622898 Novel Allergen Patented View
17751812 Core/shell Structure Platform For Immunotherapy Patented View
17121449 Compound For Regulating Gene Editing Efficiency And Application Thereof Patented View
18072963 Preservation Of Immune Response During Chemotherapy Regimens Patented View
17276394 Treatment Of Her3-Mutated Cancer By Administration Of Anti-Her3 Antibody-Drug Conjugate Patented View
19171920 Lipid Nanoparticle Formulations And Compositions Abandoned View
19064273 Anti-Ceacam5 Antibody Drug Conjugates Patented View
18087870 Neuroactive Steroid Solutions And Their Methods Of Use Abandoned View
17758268 A Drug Conjugate And Applications Thereof Abandoned View
17954037 Compositions And Methods For Linear And Conformational Site-Specific Antibodies And Methods Of Making The Same Patented View
17835419 Conjugation Linkers, Cell Binding Molecule-Drug Conjugates Containing The Linkers, Methods Of Making And Uses Such Conjugates With The Linkers Patented View
17621749 Dual Drug Antibody-Drug Conjugates Patented View
17640076 Amhrii-Binding Antibody Drug Conjugates And Their Use Thereof In The Treatment Of Cancers Abandoned View
17835311 Conjugation Linkers, Cell Binding Molecule-Drug Conjugates Containing The Linkers, Methods Of Making And Uses Such Conjugates With The Linkers Patented View
17442605 Antibody-Pyrrolobenzodiazepine Deprivative Conjugate Abandoned View
18014021 Anti-Gpc3 Antibody, Anti-Gpc3 Chimeric Antigen Receptor And Gpc3/cd3 Bispecific Antibody Patented View
17469799 Methods For Manufacturing Phthalocyanine Dye Conjugates And Stable Conjugates Patented View
18366028 Antibody-Immune Agonist Conjugate And Applications Thereof Patented View
18355341 Methods Of Treating Hematological Malignancy Using Nanoparticle Mtor Inhibitor Combination Therapy Abandoned View
17835041 Conjugation Linkers, Cell Binding Molecule-Drug Conjugates Containing The Linkers, Methods Of Making And Uses Such Conjugates With The Linkers Patented View
17612351 Antibody-Drug Conjugates And Their Use In Therapy Abandoned View
18118105 Thienoazepine Immunoconjugates, And Uses Thereof Patented View
17995005 Conjugates Abandoned View
17943711 Nk-3 Receptor Antagonists For Therapeutic Or Cosmetic Treatment Of Excess Body Fat Patented View
17284388 Compounds And Therapeutic Uses Thereof Patented View
17806037 Anti-Cd98 Antibodies And Antibody Drug Conjugates Abandoned View
17415624 Antibody-Drug Conjugates Abandoned View
17546976 Anti-Cea Immunoconjugates, And Uses Thereof Abandoned View
17835395 Conjugation Linkers, Cell Binding Molecule-Drug Conjugates Containing The Linkers, Methods Of Making And Uses Such Conjugates With The Linkers Patented View
17525780 Methods Of Using Anti-Cd79b Immunoconjugates To Treat Follicular Lymphoma Abandoned View
17793276 Macromolecular Prodrugs For Light-Emitting Diodes And Uses Thereof Patented View
16572557 Anti-Folate Receptor Antibody Conjugates, Compositions Comprising Anti-Folate Receptor Antibody Conjugates, And Methods Of Making And Using Anti-Folate Receptor Antibody Conjugates Patented View
18904628 Antibody Drug Conjugate (Adc) Targeting Nectin 4 And Comprising An Exatecan Payload Patented View
18180152 Immunomodulating Treatments Of Body Cavities Abandoned View
18010858 Humanized Antibodies Against Lewis Y Patented View
17283919 Immunomodulating Polynucleotide Conjugates And Methods Of Use Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.